Bartlett & CO. Wealth Management LLC Sells 378 Shares of Solventum Co. (NYSE:SOLV)

Bartlett & CO. Wealth Management LLC decreased its position in shares of Solventum Co. (NYSE:SOLV) by 10.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,327 shares of the company’s stock after selling 378 shares during the period. Bartlett & CO. Wealth Management LLC’s holdings in Solventum were worth $220,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the company. Global Trust Asset Management LLC increased its position in Solventum by 137.5% during the 4th quarter. Global Trust Asset Management LLC now owns 570 shares of the company’s stock worth $38,000 after buying an additional 330 shares during the period. Nisa Investment Advisors LLC increased its position in Solventum by 2.2% during the 4th quarter. Nisa Investment Advisors LLC now owns 33,546 shares of the company’s stock worth $2,216,000 after buying an additional 708 shares during the period. Strong Tower Advisory Services increased its position in Solventum by 7.4% during the 4th quarter. Strong Tower Advisory Services now owns 45,893 shares of the company’s stock worth $3,032,000 after buying an additional 3,168 shares during the period. Merit Financial Group LLC bought a new position in Solventum during the 4th quarter worth $235,000. Finally, Wedge Capital Management L L P NC increased its position in Solventum by 7.3% during the 4th quarter. Wedge Capital Management L L P NC now owns 75,283 shares of the company’s stock worth $4,973,000 after buying an additional 5,094 shares during the period.

Analyst Ratings Changes

Several research firms have weighed in on SOLV. Mizuho initiated coverage on Solventum in a research report on Wednesday, December 4th. They set a “neutral” rating and a $70.00 price objective on the stock. Stifel Nicolaus initiated coverage on Solventum in a report on Tuesday, October 8th. They set a “buy” rating and a $82.00 target price on the stock. Piper Sandler increased their target price on Solventum from $71.00 to $75.00 and gave the stock a “neutral” rating in a report on Friday, November 8th. Finally, Morgan Stanley increased their target price on Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a report on Monday, November 11th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $68.29.

Solventum Stock Up 1.8 %

NYSE:SOLV opened at $74.93 on Friday. The stock’s 50-day simple moving average is $69.41 and its 200 day simple moving average is $66.13. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45. Solventum Co. has a twelve month low of $47.16 and a twelve month high of $96.05.

Solventum (NYSE:SOLV) last released its quarterly earnings data on Thursday, November 7th. The company reported $1.15 earnings per share for the quarter, missing the consensus estimate of $1.38 by ($0.23). The company had revenue of $2.08 billion during the quarter, compared to analyst estimates of $2.05 billion. Equities analysts predict that Solventum Co. will post 6.58 earnings per share for the current fiscal year.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.